Krystal Biotech Hits Day High with 7.86% Surge Amid Strong Intraday Performance

Krystal Biotech, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has shown significant activity today, gaining 7.86% as of May 4, 2026. The stock reached an intraday high of USD 287.26, reflecting its strong performance against the broader market, where the S&P 500 declined by 0.41% on the same day. Over the past week, Krystal Biotech has increased by 5.21%, and its one-month performance stands at 9.96%. Impressively, the stock has delivered a remarkable 72.69% return over the past year, significantly outperforming the S&P 500's 26.63% gain. Year-to-date, the stock has risen by 16.39%, while the S&P 500 has only managed a 5.19% increase. Despite a low return on equity of 4.74%, Krystal Biotech has reported positive results for the last seven consecutive quarters, with a notable operating cash flow of USD 200.87 million and a net profit growth of 55.54%. The company boasts high institutional holdings at 100%, indicating strong confidence from larger investors. Overall, Krystal Biotech's performance metrics highlight its competitive position in the market.